Filed
by the Registrant ý
|
||
Filed
by a Party other than the Registrant o
|
||
Check
the appropriate box:
|
||
o
|
Preliminary
Proxy Statement
|
|
o
|
Confidential,
for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
|
|
ý
|
Definitive
Proxy Statement
|
|
o
|
Definitive
Additional Materials
|
|
o
|
Soliciting
Material Pursuant to Rule 14a-11(c) or Rule
14a-12
|
CYTORI
THERAPEUTICS, INC.
|
|||||
(Name
of Registrant as Specified In Its Charter)
|
|||||
(Name
of Person(s) Filing Proxy Statement, if other than the
Registrant)
|
|||||
Payment
of Filing Fee (Check the appropriate box):
|
|||||
ý
|
No
fee required
|
||||
o
|
Fee
computed on table below per Exchange Act Rules 14a-6(i)(4) and
0-11
|
||||
(1)
|
Title
of each class of securities to which transaction
applies:
|
||||
(2)
|
Aggregate
number of securities to which transaction applies:
|
||||
(3)
|
Per
unit price or other underlying value of transaction computed pursuant
to
Exchange Act Rule 0-11:
|
||||
(4)
|
Proposed
maximum aggregate value of transaction:
|
||||
(5)
|
Total
fee paid:
|
||||
o
|
Fee
paid previously with preliminary materials.
|
||||
o
|
Check
box if any part of the fee is offset as provided by Exchange Act
Rule
0-11(a)(2) and identify the filing for which the offsetting fee was
paid
previously. Identify the previous filing by registration statement
number,
or the Form or Schedule and the date of its filing.
|
||||
(1)
|
Amount
Previously Paid:
|
||||
(2)
|
Form,
Schedule or Registration Statement No.:
|
||||
(3)
|
Filing
Party:
|
||||
(4)
|
Date
Filed:
|
· |
Elect
directors;
|
· |
Ratify
the Audit Committee’s selection of KPMG LLP as our independent registered
public accounting firm for the 2007 fiscal year; and
|
· |
Transact
any other business that is proposed in accordance with our by-laws
before
the meeting is finally adjourned.
|
· |
“FOR”
the election of each listed nominee for director;
and
|
· |
“FOR”
ratification of KPMG LLP as our independent registered public accounting
firm for the 2007 fiscal year.
|
· |
We
may contact you using the telephone or electronic
communication;
|
· |
Directors,
officers, or other regular employees of Cytori Therapeutics may contact
you personally; or
|
· |
We
may hire agents for the sole purpose of contacting you regarding
your
proxy.
|
Name
|
Age
|
Position(s)
|
Christopher
J. Calhoun
|
41
|
Chief
Executive Officer and Director
|
Marc
H. Hedrick, MD
|
44
|
President
and Director
|
Paul
W. Hawran
|
55
|
Director
|
Ronald
D. Henriksen
|
68
|
Director
|
E.
Carmack Holmes, MD
|
69
|
Director
|
David
M. Rickey
|
51
|
Director
|
Name
and Address of Beneficial Owner (1)
|
Number
of Shares of Common Stock Owned (2)
|
Number
of Shares of Common Stock Subject to Options Exercisable Within 60
Days
(3)
|
Total
Number of Shares of Common Stock Beneficially Owned (4)
|
Percent
Ownership
|
||||
Olympus
Corporation
Shinjuku
Monolith, 3-1 Nishi-Shinjuku
2-Chome,
Shinjuku-ku, Tokyo
163-0914, Japan
|
3,013,043
|
—
|
3,013,043
|
12.8%
|
||||
Neil
Gagnon
1370
Avenue of the Americas, Suite
2002
New
York, NY 10019
|
2,291,590
|
—
|
2,291,590
|
9.7%
|
||||
Christopher
J. Calhoun
|
170,000
|
858,604
|
1,028,604
|
4.2%
|
||||
Marshall
G. Cox
|
413,116
|
385,832
|
798,948
|
3.3%
|
||||
Marc
H. Hedrick, MD
|
428,238
|
269,790
|
698,028
|
2.9%
|
||||
Mark
E. Saad
|
61,500
|
189,997
|
251,497
|
1.1%
|
||||
Seijiro
N. Shirahama
|
6,200
|
139,165
|
145,365
|
*
|
||||
John
Ransom, PhD
|
—
|
27,292
|
27,292
|
*
|
||||
Ronald
D. Henriksen
|
18,161
|
153,332
|
171,493
|
*
|
||||
David
M. Rickey
|
27,609
|
128,332
|
155,941
|
*
|
||||
E.
Carmack Holmes, MD
|
13,161
|
99,165
|
112,326
|
*
|
||||
Paul
W. Hawran
|
—
|
36,666
|
36,666
|
*
|
||||
All
executive officers and directors as a group (13)
|
1,143,378
|
2,592,028
|
3,735,406
|
14.3%
|
*
|
Represents
beneficial ownership of less than one percent (1%) of the outstanding
shares as of April 15, 2007.
|
(1)
|
Unless
otherwise indicated, the address of each of the named individuals
is c/o
Cytori Therapeutics, Inc., 3020 Callan Road, San Diego, CA 92121.
|
(2)
|
Represents
shares of outstanding common stock owned by the named parties as
of April
15, 2007.
|
(3)
|
Shares
of common stock subject to stock options currently exercisable or
exercisable within 60 days of April 15, 2007 are deemed to be outstanding
for computing the percentage ownership of the person holding such
options
and the percentage ownership of any group of which the holder is
a member,
but are not deemed outstanding for computing the percentage of any
other
person.
|
(4)
|
The
amounts and percentages of common stock beneficially owned are reported
on
the basis of regulations of the Securities and Exchange Commission
governing the determination of beneficial ownership of securities.
Under
the rules of the Commission, a person is deemed to be a “beneficial owner”
of a security if that person has or shares “voting power,” which includes
the power to vote or to direct the voting of such security, or “investment
power,” which includes the power to dispose of or to direct the
disposition of such security. A person is also deemed to be a beneficial
owner of any securities for which that person has a right to acquire
beneficial ownership within 60
days.
|
Name
|
Age
|
Position
|
Christopher
J. Calhoun
|
41
|
Chief
Executive Officer
|
Marc
H. Hedrick, MD
|
44
|
President
|
Mark
E. Saad
|
37
|
Chief
Financial Officer
|
Bruce
A. Reuter
|
58
|
Senior
Vice President — International Sales, Marketing &
Distribution
|
Seijiro
N. Shirahama
|
53
|
Senior
Vice President — Asia Pacific
|
Douglas
Arm, Ph.D.
|
38
|
Vice
President — Development - Regenerative Cell Technology
|
Alexander
M. Milstein, MD
|
48
|
Vice
President — Clinical Development
|
John
T. Ransom, Ph.D.
|
52
|
Vice
President — Research - Regenerative Cell
Technology
|
· |
align
the financial interests of our executives with those of our stockholders;
|
· |
attract,
motivate and retain the executive talent required to successfully
implement our business strategy; and
|
· |
provide
incentives for achieving our short-term and long-term
goals.
|
Officer
and Position
|
Bonus
Potential as a % of Salary
|
Company
Performance Weighting
|
Individual
Performance Weighting
|
Bonus
Awarded as a % of Salary
|
||||
Christopher
J. Calhoun,
Chief
Executive Officer
|
40%
|
50%
|
50%
|
29%
|
||||
Mark
E. Saad,
Chief
Financial Officer
|
25%
|
50%
|
50%
|
18%
|
||||
Marc
H. Hedrick,
President
|
30%
|
50%
|
50%
|
23%
|
||||
Seijiro
N. Shirahama,
Sr.
Vice President - Asia Pacific
|
20%
|
50%
|
50%
|
16%
|
||||
John
Ransom,
Vice
President - RCT
|
15%
|
50%
|
50%
|
12%
|
· |
Initiating
clinical trials in at least two therapeutic
applications;
|
· |
Completing
bone, soft tissue and cardiac preclinical
work;
|
· |
Improving
against the Company’s budgeted results of $28.8 million loss;
and
|
· |
Increasing
the Company’s stock visibility and
liquidity.
|
1. |
our
understanding of the incentivization power of stock options in
companies
such as this one;
|
2. |
an
assessment of the number of incentivizing stock options (either
in-the-money or underwater) already held by our Named Executive
Officers
and other employees on a group basis; and
|
3. |
an
assessment of general industry economic
conditions.
|
(a)
|
(b)
|
(c)
|
(d)
|
(e)
|
(f)
|
(g)
|
(h)
|
(i)
|
(j)
|
|||||||||
Name
and Principal Position
|
Year
|
Salary
|
Bonus(1)
|
Stock
Awards
|
Option
Awards(2)
|
Non-Equity
Incentive Plan Comp.
(3)
|
Change
in Pension Value and NQ Deferred Comp.
|
All
Other Compen-sation
|
Total
|
|||||||||
Christopher
J. Calhoun,
Chief
Executive Officer (PEO)
|
2006
|
$
395,002
|
|
—
|
|
—
|
|
$
250,592
|
|
$
121,800
|
|
—
|
|
$18,588(4)
|
|
$
786,342
|
||
Mark
E. Saad,
Chief
Financial Officer (PFO)
|
2006
|
$
329,169
|
|
—
|
|
—
|
|
$
232,433
|
|
$
63,438
|
|
—
|
|
$10,838(5)
|
|
$
635,878
|
||
Marc
H. Hedrick,
President
|
2006
|
$
331,669
|
|
—
|
|
—
|
|
$
170,767
|
|
$
84,863
|
|
—
|
|
$13,764(6)
|
|
$
601,062
|
||
Seijiro
N. Shirahama,
Sr.
Vice President -
Asia
Pacific
|
2006
|
$
214,810
|
|
—
|
|
—
|
|
$
227,636
|
|
$
36,425
|
|
—
|
|
—(7)
|
|
$
480,958
|
||
John
Ransom,
Vice
President -
Regenerative
Cell Tech.
|
2006
|
$
183,337
|
|
—
|
|
—
|
|
$
208,139
|
|
$
24,000
|
|
—
|
|
$10,781(8)
|
|
$
426,256
|
(1)
|
Column
(d) is used to record non-equity discretionary (non-incentive based)
bonuses made to our NEO’s. We did not provide such bonuses in 2006,
therefore nothing is reflected in this column. Cash bonuses paid
under our
EMIC Plan are disclosed in column
(g).
|
(2)
|
This
column represents the dollar amount recognized for financial statement
reporting purposes with respect to the 2006 fiscal year for the fair
value
of stock options granted to each of the named executives, in 2006
as well
as prior fiscal years, in accordance with FAS 123R. Pursuant to the
SEC
rules, the amounts shown exclude the impact of estimated forfeitures
related to service-based vesting conditions. For
additional information on the valuation assumptions with respect
to the
2006 grants, refer to note 18 of the financial statements in our
Annual
Report on Form 10-K, as filed with the SEC on April 2, 2007.
|
(3)
|
The
amounts in column (g) reflect the cash awards under the 2006 EMIC
Plan,
which is discussed in further detail in the CD&A under the heading
“Annual Bonus.”
|
(4)
|
All
Other Compensation for Mr. Calhoun for 2006 includes supplemental
long-term disability insurance premiums ($3,433), supplemental term
life
insurance premiums ($2,155), an automobile allowance ($11,000), and
a tax
preparation fee allowance ($2,000).
|
(5)
|
All
Other Compensation for Dr. Hedrick for 2006 includes supplemental
long-term disability insurance premiums ($1,764), an automobile allowance
($10,000), and a tax preparation fee allowance
($2,000).
|
(6)
|
All
Other Compensation for Mr. Saad for 2006 includes supplemental long-term
disability insurance premiums ($838), an automobile allowance ($8,000),
and a tax preparation fee allowance
($2,000).
|
(7)
|
Dollar
value of Mr. Shirahama’s 2006 perquisites and other personal benefits was
less than $10,000.
|
(8)
|
All
Other Compensation for Dr. Ransom for 2006 includes supplemental
long-term
disability insurance premiums ($781), an automobile allowance ($8,000),
and a tax preparation fee allowance
($2,000).
|
(a)
|
(b)
|
(c-e)
|
(f-h)
|
(i)
|
(j)
|
(k)
|
(l)
|
(m)
|
||||||||||||||||
Potential
2006 Payouts Under Non-Equity Incentive Plan
Awards
|
Estimated
Future Payouts Under Equity Incentive Plan Awards
|
All
Other Stock Awards:
|
All
Other Option Awards:
|
Exercise
or
|
Full
Grant Date Fair
|
|||||||||||||||||||
Named
Officers
|
Grant
Date
|
Thresh-old
($)
|
Target
($)
|
Maxi-mum
($)
|
Thresh-old
(#)
|
Target
(#)
|
Maxi-mum
(#)
|
Number
of Shares of Stock or Units
(#)
|
Number
of Securities Underlying Options
(#)
|
Base
Price of Option Awards ($/Sh)(1)
|
Market
Price on Date of Grant
($/Sh)
|
Value
of Stock and Option Awards ($)(2)
|
||||||||||||
Christopher
J. Calhoun,
Chief
Executive Officer (PEO)
|
1/24/2006
|
-
|
$168,000
|
-
|
-
|
-
|
-
|
-
|
100,000
|
$7.04
|
$7.40
|
$499,000
|
||||||||||||
Mark
E. Saad,
Chief
Financial Officer (PFO)
|
1/24/2006
|
-
|
$87,500
|
-
|
-
|
-
|
-
|
-
|
70,000
|
$7.04
|
$7.40
|
$349,300
|
||||||||||||
Marc
H. Hedrick,
President
|
1/24/2006
|
-
|
$109,500
|
-
|
-
|
-
|
-
|
-
|
70,000
|
$7.04
|
$7.40
|
$349,300
|
||||||||||||
Seijiro
N. Shirahama,
Sr.
Vice President - Asia Pacific
|
1/24/2006
|
-
|
$47,000
|
-
|
-
|
-
|
-
|
-
|
35,000
|
$7.04
|
$7.40
|
$174,650
|
||||||||||||
John
Ransom,
Vice
President - RCT
|
1/24/2006
|
-
|
$33,000
|
-
|
-
|
-
|
-
|
-
|
35,000
|
$7.04
|
$7.40
|
$175,350
|
(1) |
Under
our 1997 and 2004 Plans, grants of stock options must have an exercise
price equal to or greater than their “fair market value” on the grant
date. Until January 1, 2007, our “fair market value” was defined as the
closing price of our common stock on the Nasdaq Global Market on
the day
immediately preceding the grant date. In November 2006, our Board
of
Directors adopted a policy to, beginning January 1, 2007, define
the fair
market value of our common stock for purposes of granting new stock
options under the 1997 and 2004 Plan as the closing price of our
common
stock as quoted on the Nasdaq Global Market on the grant date.
|
(2) |
Computed
in accordance with FAS 123R. See note 18 of the financial statements
in
our Annual Report on Form 10-K, as filed with the SEC on April 2,
2007
regarding assumptions underlying valuation of equity awards.
|
(a)
|
(b)
|
(c)
|
(d)
|
(e)
|
(f)
|
(g)
|
(h)
|
(i)
|
(j)
|
(k)
|
||||||||||
Option
Awards
|
Stock
Awards
|
|||||||||||||||||||
Name
|
Option
Grant Date(1)
|
Number
of
Securities
Underlying Unexercised Options
(#)
Exercisable
|
Number
of Securities Underlying Unexercised Options
(#)
Un-Exercisable
(2)
|
Equity
Incentive Plan Awards: Number of Securities Underlying Unexercised
Unearned Options
(#)
|
Option
Exercise Price
($)
|
Option
Ex-piration Date
|
Number
of Shares or Units of Stock That Have Not Vested
(#)
|
Market
Value of Shares or Units of Stock That Have Not
Vested
($)
|
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other
Rights
That Have Not Vested
(#)
|
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares,
Units or
Other Rights That Have Not Vested
($)
|
||||||||||
Christopher
J. Calhoun,
Chief
Executive Officer (PEO)
|
1/1/1999
1/1/2000
1/3/2001
2/8/2002
1/28/2003
6/2/2004
2/2/2005
1/24/2006
|
53,190
62,500
200,000
205,000
195,830
46,874
45,833
22,916
|
—
—
—
—
4,170
28,126
54,167
77,084
|
—
—
—
—
—
—
—
—
|
$0.15
$3.00
$7.06
$3.09
$4.40
$4.16
$3.12
$7.04
|
1/1/2009
1/1/2010
1/3/2011
2/8/2012
1/28/2013
6/2/2014
2/2/2015
1/24/2016
|
—
—
—
—
—
—
—
—
|
—
—
—
—
—
—
—
—
|
—
—
—
—
—
—
—
—
|
—
—
—
—
—
—
—
—
|
||||||||||
Mark
E. Saad,
Chief
Financial Officer (PFO)
|
6/21/2004
2/2/2005
1/24/2006
|
118,748
32,083
16,041
|
71,252
37,917
53,959
|
—
—
—
|
$4.12
$3.12
$7.04
|
6/21/2014
2/2/2015
1/24/2016
|
—
—
—
|
—
—
—
|
—
—
—
|
—
—
—
|
||||||||||
Marc
H. Hedrick,
President
|
11/14/2002
1/28/2003
6/2/2004
2/2/2005
1/24/2006
|
150,000
24,478
31,249
32,083
16,041
|
—
522
18,751
37,917
53,959
|
—
—
—
—
—
|
$4.15
$4.40
$4.16
$3.12
$7.04
|
11/14/2012
1/28/2013
6/2/2014
2/2/2015
1/24/2016
|
—
—
—
—
—
|
—
—
—
—
—
|
—
—
—
—
—
|
—
—
—
—
—
|
||||||||||
Seijiro
N. Shirahama,
Sr.
Vice President - Asia Pacific
|
10/28/2002
6/2/2004
2/2/2005
12/8/2005
1/24/2006
|
75,000
15,624
16,041
12,500
8,021
|
—
9,376
18,959
37,500
26,979
|
—
—
—
—
—
|
$4.14
$4.16
$3.12
$6.86
$7.04
|
10/28/2012
6/2/2014
2/2/2015
12/8/2015
1/24/2016
|
—
—
—
—
—
|
—
—
—
—
—
|
—
—
—
—
—
|
—
—
—
—
—
|
||||||||||
John
Ransom,
Vice
President - RCT
|
12/19/2005
1/24/2006
|
12,500
—
|
37,500
35,000
|
—
—
|
$7.44
$7.04
|
12/19/2015
1/24/2016
|
—
—
|
—
—
|
—
—
|
—
—
|
(1) |
For
a better understanding of this table, we have included an additional
column showing the grant date of the stock options.
|
(2) |
Generally,
awards issued under the 1997 or 2004 plans are subject to four-year
vesting, and have a contractual term of 10 years. Awards presented
in this
table contain one of the following two vesting provisions:
|
· |
25%
of a granted award vests after one year of service, while an additional
1/48 of the award vests at the end of each month thereafter for 36
months,
or
|
· |
1/48
of the award vests at the end of each month over a four-year period.
|
(a)
|
(b)
|
(c)
|
(d)
|
(e)
|
||||
Option
Awards
|
Stock
Awards
|
|||||||
Name
|
Number
of Shares Acquired on Exercise
(#)
|
Value
Realized on Exercise
($)
|
Number
of Shares Acquired on Vesting
(#)
|
Value
Realized on Vesting
($)
|
||||
Christopher
J. Calhoun,
Chief
Executive Officer (PEO)
|
53,060
|
$400,597
|
—
|
—
|
||||
Mark
E. Saad,
Chief
Financial Officer (PFO)
|
—
|
—
|
—
|
—
|
||||
Marc
H. Hedrick,
President
|
—
|
—
|
—
|
—
|
||||
Seijiro
N. Shirahama,
Sr.
Vice President - Asia Pacific
|
—
|
—
|
—
|
—
|
||||
John
Ransom,
Vice
President - RCT
|
—
|
—
|
—
|
—
|
(a)
|
(b)
|
(c)
|
(d)
|
(e)
|
(f)
|
(g)
|
(h)
|
|||||||
Director
Name(1)
|
Fees
Earned or Paid in Cash(2)
($)
|
Stock
Awards
($)
|
Option
Awards(4) (5)
($)
|
Non-Equity
Incentive Plan Compensation ($)
|
Change
in Pension Value and Nonqualified Deferred Compensation Earnings
($)
|
All
Other Compensation ($)
|
Total
($)
|
|||||||
Marshall
G. Cox, Chairman(6)
|
$88,500
|
(3) |
-
|
$130,813
|
-
|
-
|
-
|
$219,313
|
||||||
Paul
Hawran
|
$46,000
|
-
|
$74,613
|
-
|
-
|
-
|
$120,613
|
|||||||
Ronald
Henriksen(6)
|
$48,000
|
-
|
$90,654
|
-
|
-
|
-
|
$138,564
|
|||||||
E.
Carmack Holmes, MD
|
$28,500
|
-
|
$92,715
|
-
|
-
|
-
|
$121,215
|
|||||||
David
Rickey
|
$41,000
|
-
|
$88,347
|
-
|
-
|
-
|
$129,347
|
(1)
|
Mr.
Calhoun and Dr. Hedrick are not included in this table as they are
employees of the Company and receive no extra compensation for their
services as a Director. The compensation received by Mr. Calhoun
and Dr.
Hedrick as employees of the Company is shown in the Summary Compensation
Table and the three stock-option-related tables
above.
|
(2)
|
Each
non-employee director and Mr. Cox receive a $5,000 quarterly retainer,
a
fee of $2,000 per quarterly meeting attended, and a fee of $2,000
per
special meeting attended in person. Attendance of telephonic meetings
is
compensated at $500 per meeting. Compensation Committee members receive
$1,000 per meeting attended, Governance and Nominating Committee members
receive $2,000 per meeting attended, Audit Committee members receive
$2,000 per meeting attended, and Special Pricing Committee members
receive
$500 per meeting attended. The Chairmen of the Audit Committee and
the
Governance and Nominating Committee each receive an additional annual
stipend of $5,000.
|
(3)
|
Mr.
Cox was employed by us in 2006 in his capacity of Chairman of the
Board.
His 2006 salary was $60,000, and he received standard employee medical
benefits.
|
(4)
|
Column
(d) represents the dollar amount recognized for financial statement
reporting purposes with respect to the 2006 fiscal year for the
fair value
of stock options previously granted to the directors, in 2006 as
well as
prior fiscal years, in accordance with FAS 123R. Pursuant to the
SEC
rules, the amounts shown exclude the impact of estimated forfeitures
related to service-based vesting conditions. For additional information
on
the valuation assumptions with respect to the 2006 grants, refer
to note
18 of the financial statements in our Annual Report on Form 10-K,
as filed
with the SEC on April 2, 2007.
|
(5)
|
As
of December 31, 2006, the following directors held options to purchase
the
respective number of shares of our common stock: Marshall Cox 460,000,
Paul Hawran 85,000, Ronald Henriksen 205,000, E. Carmack Holmes
155,000,
David Rickey 180,000.
|
(6)
|
Mr.
Cox was our Chairman of the Board until April 26, 2007. As of April
26,
2007, Mr. Henriksen is serving as our Interim Chairman of the Board.
|
Equity
Compensation Paid to Directors for Fiscal Year
2006
|
||||||||||||
(a)
|
(b)
|
(c)
|
(d)
|
(e)
|
(f)
|
(g)
|
||||||
Director
Name
|
Grant
Date
|
Option
Awards
(#)
|
Grant
Date Fair Value of Option Awards(1)
($)
|
Stock
Awards
(#)
|
Grant
Date Fair Value of Stock Awards
($)
|
Total
Value of Equity Awards for 2006
($)
|
||||||
Marshall
G. Cox, Chairman(2)
|
4/6/2006
|
50,000
|
$309,440
|
-
|
-
|
$309,440
|
||||||
Paul
W. Hawran
|
4/6/2006
|
35,000
|
$216,608
|
-
|
-
|
$216,608
|
||||||
Ronald
Henriksen(2)
|
4/6/2006
|
35,000
|
$216,608
|
-
|
-
|
$216,608
|
||||||
E.
Carmack Holmes, MD
|
4/6/2006
|
35,000
|
$216,608
|
-
|
-
|
$216,608
|
||||||
David
Rickey
|
4/6/2006
|
35,000
|
$216,608
|
-
|
-
|
$216,608
|
(1)
|
The
grant date fair value of all option awards granted to the directors
and
all Named Executive Officers in 2006 was $6.19 per
share.
|
(2)
|
Mr.
Cox was our Chairman of the Board until April 26, 2007. As of April
26,
2007, Mr. Henriksen is serving as our Interim Chairman of the Board.
|
Plan
Category
|
Number
of securities to be issued upon exercise of outstanding options,
warrants
and rights
|
Weighted-average
exercise
price
of outstanding options, warrants and rights
|
Number
of securities remaining available for future issuance under equity
compensation plans (excluding securities reflected in column
(a))
|
|||
(a)
|
(b)
|
(c)
|
||||
|
|
|||||
Equity
compensation plans approved by security holders
|
4,409,286
|
$4.22
|
430,653
|
|||
Equity
compensation plans not approved by security holders(1)
|
1,524,743
|
$5.80
|
2,413,691
|
|||
Total
|
5,934,029
|
$4.62
|
2,844,344
|
(1)
|
The
maximum number of shares shall be cumulatively increased on the first
January 1 after the Effective Date, August 24, 2004, and each January
1
thereafter for 9 more years, by a number of shares equal to the lesser
of
(a) 2% of the number of shares issued and outstanding on the immediately
preceding December 31, and (b) a number of shares set by the
Board.
|
2006
|
2005
|
||
Audit
fees (1)
|
$
524,427
|
$
491,474
|
|
Audit
related fees (2)
|
—
|
—
|
|
Tax
Fees (3)
|
$
22,253
|
$
70,128
|
|
All
other fees (4)
|
—
|
—
|
|
Total
|
$
546,680
|
$
559,602
|
(1) ((1)
|
Audit
fees consist of fees for professional services performed by KPMG
LLP for
the integrated audit of our annual financial statements (and internal
control over financial reporting) included in our Form 10-K filing
and
review of financial statements included in our quarterly Form 10-Q
filings, reviews of registration statements and issuances of consents,
and
services that are normally provided in connection with statutory
and
regulatory filings or engagements.
|
((2) (2)
|
Audit
related fees consist of fees for assurance and related services performed
by KPMG LLP that are reasonably related to the performance of the
audit or
review of our financial statements. No such fees were incurred in
2005 or
2006.
|
(3) ((3)
|
Tax
fees consist of fees for professional services performed by KPMG
LLP with
respect to tax compliance, tax advice and tax planning. In 2005,
these
fees were related to the preparation of tax returns in the United
States,
FAS 109 training, and tax advice regarding the Olympus transactions.
In
2006, these fees were related to the preparation of tax returns and
tax
advice and consultation related to stock options and the implementation
of
FAS 123R.
|
(4) ((4)
|
All
other fees consist of fees for other permissible work performed by
KPMG
LLP that does not meet with the above category descriptions. No such
fees
were incurred in 2005 or 2006.
|
COMPUTERSHARE,
INC.
250 ROYALL STREET
CANTON, MA 02021
|
VOTE BY INTERNET - www.proxyvote.com
Use
the
Internet to transmit your voting
instructions and for electronic
delivery of information up until 11:59 P.M. Eastern
Time the day before the
cut-off
date or meeting date. Have your
proxy card in hand when
you
access
the web
site and follow the instructions to obtain your records and
to create an electronic voting instruction form.
ELECTRONIC DELIVERY OF FUTURE STOCKHOLDER
COMMUNICATIONS
If you would like to reduce the costs incurred by Cytori Therapeutics, Inc.
in mailing proxy materials, you can consent to receiving all future proxy
statements, proxy cards and annual reports electronically via e-mail or the
Internet. To sign up for electronic delivery, please follow the instructions
above to vote using the Internet and, when prompted, indicate that you
agree to receive or access stockholder communications electronically in
future
years.
VOTE BY PHONE - 1-800-690-6903
Use any touch-tone telephone to transmit your voting instructions up until
11:59 P.M. Eastern Time the day before the cut-off date or meeting date.
Have your proxy card in hand when you call and then follow the instructions.
VOTE BY MAIL
Mark,
sign and date your proxy card
and return it in the
postage-paid
envelope
we have provided or return it to
Cytori Therapeutics, Inc.,
c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.
|
TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: |
CYTTH1 KEEP THIS PORTION FOR YOUR RECORDS
|
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - | - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - |
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. | DETACH AND RETURN THIS PORTION ONLY |
CYTORI THERAPEUTICS, INC. | |
|
|
Vote On Directors | Vote On Proposal |
1. The Board of Directors recommends a vote
FOR each of the listed director nominees.
|
For
|
Against
|
Abstain
|
The
Board
of
Directors
recommends
a
vote
FOR
the
following
proposal.
|
For
|
Against
|
Abstain
|
|
1a -
Christopher J. Calhoun
|
o
|
o
|
o
|
2.
To ratify the selection of KPMG LLP
as
independent
registered public accounting
firm
of
Cytori for the fiscal year
ending
|
o
|
o
|
o
|
|
1b -
Paul W. Hawran
|
o
|
o
|
o
|
December 31, 2007
|
||||
1c -
Marc H. Hedrick, MD
|
o
|
o
|
o
|
3.
By my signature below, I confer to the named
proxies
discretionary authority on any other business that may properly come
before the
|
o
|
o
|
o
|
|
1d -
Ronald D. Henriksen
|
o
|
o
|
o
|
Annual
Meeting
or any adjournment or postponement of the Annual Meeting.
|
||||
1e -
E. Carmack Holmes, MD
|
o
|
o
|
o
|
|||||
1f
-
David M. Rickey
|
o
|
o
|
o
|
Please sign exactly as your name appears on this card. When signing as
an attorney, executor, administrator, trustee or guardian, please give your
full title. If shares are held jointly, each stockholder should sign.
|
||
Signature [PLEASE SIGN WITHIN BOX] Date | Signature (Joint Owners) Date |
Proxy
-
CYTORI
THERAPEUTICS,
INC.
|
PROXY SOLICITED BY THE BOARD OF DIRECTORS
FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 2, 2007
The undersigned hereby appoints Christopher J. Calhoun and Marc H. Hedrick, MD, or either of them, as proxy holders each
with full power of substitution, to appear on behalf and to vote all shares of common stock of Cytori Therapeutics, Inc.
(the "Company") that the undersigned is entitled to vote at the Annual Meeting of Stockholders of the Company to be held on
August 2, 2007, and at any postponement or adjournment thereof.
When properly executed, this proxy will be voted as directed. If properly executed and no instructions are specified, this proxy
will be voted FOR the election of the listed Nominees as Directors and FOR the ratification of the selection of KPMG LLP to
function as the Company's Independent Registered Public Accounting firm.
PLEASE COMPLETE, DATE AND SIGN THIS PROXY AND RETURN IT IN THE ACCOMPANYING ENVELOPE.
|